More than 80,000 healthcare workers and their communities from across the country and around the world joined together in the Medline Pink Glove Dance for breast cancer online video competition. After a hard-fought dance battle, the online votes are in and Medline is pleased to name Geisinger Health System, Danville, Pa., as the winner. As a result, $25,000 will be donated to their charity of choice, the American Cancer Society, providing free transportation for treatment to central Pennsylvania breast cancer patients in need. Additionally, Medline and participating hospitals will donate another $1 million to the National Breast Cancer Foundation and various local breast cancer charities nationwide. More than $2.2 million has been donated through the campaign and Medline Foundation since 2005.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64450-medline-pink-glove-dance-video-competition-winners-breast-cancer-education
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment
Danica Patrick will take to the track with a new primary sponsor as the blue-and-white No. 10 Aspen Dental Chevrolet SS makes its debut at the Kobalt 400 NASCAR Sprint Cup Series race at Las Vegas Motor Speedway this weekend. And she’ll do it sporting a blue firesuit selected by fans who voted in the Danica's New Suit Sweepstakes.
Patrick first teamed up with Aspen Dental, one of the largest and fastest-growing networks of dental care providers in the U.S. with more than 430 locations in communities across 27 states, last fall. Since that time, she has helped to shine a spotlight on an often overlooked healthcare issue – oral health – by championing the launch of Aspen Dental's Healthy Mouth Movement, a community-giving initiative designed to deliver free dental care to thousands of people in need in communities across the U.S., and oral health education to millions more.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/66081-aspen-dental-danica-patrick-new-primary-sponsor-las-vegas-motor-speedway
LLNS, a leading healthcare communications company and part of Diversified Agency Services (DAS), is pleased to announce that Sharon Callahan, CEO of LLNS, has been recognized by the Women’s Venture Fund with its “Highest Leaf Award”. The award celebrates exceptional women who have demonstrated remarkable business leadership, developed a vision for business success and made outstanding contributions to their respective industries.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7234651-llns-sharon-callahan-business-leadership-women-s-venture-fund-healthcare
‘Tackling hepatitis C: Moving towards an integrated policy approach’, a report published by The Economist Intelligence Unit (EIU) today reveals that many countries around the world have been slow to respond with national policies on hepatitis C despite recent government pledges to fight the disease. The hepatitis C virus remains the leading cause of liver cancer, liver disease and liver transplantation placing a huge burden on patients' lives and healthcare systems.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400562-janssen-new-reports-hepatitis-c
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
The European Head and Neck Society (EHNS) today announces European-wide ‘Early Diagnosis Days’ taking place on Wednesday 24 September as part of this year’s Head and Neck Cancer Awareness Week (22–26 September). This follows the success of the 2013 campaign, where nearly 100 ‘Early Diagnosis Days’ took place. More than 5,000 patients were seen by a healthcare provider in 1 day, resulting in a referral rate of approximately 5% and multiple diagnoses of the disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762527-EHNS-early-diagnosis-days/
Strategic Partners, Inc., the leader in the manufacturing and marketing of medical apparel, lab wear, footwear and accessories, today announced the launch of its next generation of medical apparel: scrubs, lab wear and accessories protected with CERTAINTY™ antimicrobial technology.
On a daily basis, many healthcare professionals are exposed to unwanted bacteria on their clothing. CERTAINTY antimicrobial technology can provide more fabric protection than traditional scrubs, giving healthcare professionals the freedom to perform their duties in comfortable, fashion-inspired clothing.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7458151-strategic-partners-certainty/
Bayer Healthcare, the makers of Coppertone®, kicked off an exciting multi-year deal with U.S. Soccer and the National Women’s Soccer League to encourage the use of sun protection on and off the field and help soccer fans across the country enjoy every minute of the game. Christen Press, star forward for the U.S. Women’s National Team, will be joined by fellow soccer stars Graham Zusi, Kelley O’Hara, and Matt Besler as brand ambassadors for Coppertone.
“I’m so excited to be a Coppertone brand ambassador because as an athlete, taking care of my body is a huge part of my job and sunscreen is a vital part of that,” said Press. “Whether I’m running up and down the field or running errands, I make it a point to ensure that my skin is protected. Everyone, especially athletes and fans everywhere, need to make sunscreen and sun protection a priority.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7325851-bayer-coppertone-women-s-soccer-sun/
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
